Successful erlotinib rechallenge after both gefitinib- and erlotinib-induced interstitial lung diseases

Epidermal growth factor receptor tyrosine kinase inhibitors, gefitnib and erlotinib, are effective for advanced nonsmall-cell lung cancer with epidermal growth factor receptor gene mutation. However, interstitial lung disease induced by these drugs is sometimes fatal, and discontinuation of the medi...

Descripción completa

Detalles Bibliográficos
Autores principales: Arakawa, Nobuhito, Tsujita, Akihiro, Saito, Noriko, Ishikawa, Shigemi, Ohno, Shoji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2013
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4184641/
https://www.ncbi.nlm.nih.gov/pubmed/25473530
http://dx.doi.org/10.1002/rcr2.12

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4184641/
https://www.ncbi.nlm.nih.gov/pubmed/25473530
http://dx.doi.org/10.1002/rcr2.12

Ejemplares similares